Wednesday, May 18, 2022

RedHill Biopharma Ltd. (RDHL) Stock Continuously Rising, Here’s Why

RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company, has increased by 6.56% in the premarket trading session. As a result, RDHL stock is changing hands at $5.20 at the time of this writing. On Monday, RDHL stock rose 11.67% in regular trading session and closed the day at $4.88. The continuous rise of RDHL stock could presumably be related to the presentation of analysis about phase 2/3 data.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


RDHL reported data from the study

On Monday, RDHL reported new data from opaganib global Phase 2/3 study. The study was carried out in hospitalized patients with severe Covid-19. The study showed that the treatment with oral opaganib (ABC294640) as compared to placebo-controlled arm caused a reduction of 62% in mortality. Besides that, there was a significant improvement in time to room air and median time to hospital discharge in a group of 251 hospitalized. They were all moderately severe Covid-19 patients and comprised 53% of 475 study participants. The company said that the results were from a post-hoc analysis of data from 251 of the study participants; it required a fraction of inspired Oxygen up to 60% at the baseline. The patients having a fraction of inspired oxygen less than or equal to 60% were considered to be severely affected. They required oxygen supplementation. Mark L. Levitt, MD, PhD, Medical Director at RedHill, said that the findings support the potential for opaganib’s use in hospitalized, moderately severe COVID-19 patients.

RDHL stock Q2 2021 financial results


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


On 26th August, RDHL reported the quarterly results for the second quarter of the fiscal year 2021, which ended 30th June 2021. According to the details, the company generated net revenues of $21.50 million during the quarter. Compared to that, during the equivalent period of 2020, the net revenues stood at $20.89 million. The gross profit for three month period stood at $10.91 million, while during the equivalent period of 2020, it was $6.71 million. The total expenses for the period stood at $35.79 million. During the equivalent period of 2020, the total expenses were $19.21 million. The net loss for the period was $29.12 million (or $0.06 per basic and diluted share). Compared to that, the net loss for the equivalent three month period of 2020 was $16.04 million (or $0.04 per basic and diluted share). The company had cash and cash equivalents of $51.81 million on 30th June. The total stood at $203.67 million, while total liabilities were $174.09 million.

What’s ahead for RDHL?

Recent past performance indicators are revealing a grim picture for RDHL stock. The stock has declined by 51% during the last month, the primary reason being a failure in the performance of opaganib at various fronts. But as the recent study results have shown, RDHL stock could rise monumentally within the future based upon its innovation strategy.

Latest news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

Related news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam